Data powered by Alphabet Inc.
Ajanta Pharmaceuticals
AJANTPHARM
₹ 2,396.07
- ₹ 2.78
-0.11%
Ajanta Pharmaceuticals Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 23,928 |
| Weekly | 5.40% | 2,83,425 |
| Monthly | 3.63% | 25,25,665 |
Ajanta Pharmaceuticals Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| AJANTPHARM | - | 5.40% | 3.63% |
| Index | - | - | - |
| Peer Avg. | -0.04% | 5.38% | 11.47% |
*Avg of index constituents
Ajanta Pharmaceuticals Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| AJANTPHARM | 14.38 | 4.80 | 14.89 | 23.28 | 29.71 | 0.81 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
*Avg of index constituents
Ajanta Pharmaceuticals Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 15.57% | 7.77% | 23.28% | 29.71% |
| FY '20-21 | 17.72% | 46.48% | 24.33% | 33.10% |
| FY '19-20 | 24.91% | 16.73% | 19.24% | 27.23% |
Ajanta Pharmaceuticals Shareholding Pattern
Promoters : 70.48%
FII : 8.64%
DII : 12.74%
Public : 8.14%
Others : 0%
Ajanta Pharmaceuticals Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 3,240.82 | 2,330.72 | 1,037.80 | 716.27 |
| FY '20-21 | 2,804.14 | 1,846.40 | 1,022.51 | 664.75 |
| FY '19-20 | 2,392.14 | 1,784.10 | 746.25 | 454.42 |
All values are in crores
Ajanta Pharmaceuticals Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| AJANTPHARM | 3,240.82 | 2,330.72 | 1,037.80 | 716.27 |
| SUVENPHAR | 1,320.22 | 738.22 | 722.09 | 485.40 |
| JBCHEPHARM | 2,307.06 | 1,781.39 | 565.10 | 373.52 |
All values are in crores
Ajanta Pharmaceuticals Share Price
Ajanta Pharma Limited is an Indian company primarily engaged in the development, manufacture and distribution of ready-made specialty medicines. The company's marketing network operates in domestic and international markets. The company produces a wide range of specialty products targeting different therapeutic segments for patient care and tailored to each market area in which it operates. The generic sea trade is spread across India and about 30 developing countries in Africa, Southeast Asia and West Asia and the Commonwealth of Independent States (CIS). Its product range includes advanced technology products. The company has also made significant investments in its research and development (R&D) facilities.